Clinical Trials · NCT00230594

Desmopressin Response in the Young

CompletedPhase 3Desmopressin (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Ferring Pharmaceuticals
Enrollment
132
Start date
Jul 2004
Locations
9 sites, Canada
Primary endpoint
To evaluate the efficacy of desmopressin administered as a melt tablet compared to placebo in terms of reducing the number of wet nights in children and adolescents with primary nocturnal enuresis.
View Desmopressin compound reference